All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 2, 2023
Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
Substance use and poisoning RSS Feed RSS

Man sitting on bed holding head
Neurology/Psychiatric

Psilera nominates non-hallucinogenic psilocybin derivative as lead clinical candidate

May 26, 2023
No Comments
Psilera Inc. has selected a novel, non-hallucinogenic psilocybin derivative, PSIL-006...
Read More
Vaccine vial and syringe
Substance Use & Poisoning

TLR7/8 agonist enhances efficacy of M-sKLH vaccine for opioid use disorder

May 24, 2023
No Comments
At the recent ASPET meeting, University of Minnesota and University of Montana researchers presented data from studies to determine the ability of the Toll-like receptor 7 (TLR7) and TLR8 agonist INI-4001 to enhance the efficacy of the heroin vaccine M-sKLH for the treatment of opioid use disorder.
Read More
Woman receiving chemotherapy
Substance Use & Poisoning

Onquality receives IND clearance for OQL-036 for capecitabine-induced hand-foot syndrome

May 2, 2023
No Comments
Onquality Pharmaceuticals LLC has received FDA clearance of its IND application for OQL-036, a potential prophylactic treatment for capecitabine-induced hand-foot syndrome (HFS).
Read More
Substance Use & Poisoning

State University of New Jersey presents new GABA-A receptor PAMs for alcoholism

May 2, 2023
No Comments
State University of New Jersey (Rutgers) has divulged flavonoids acting as GABA-A receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of alcoholism.
Read More
Neon brain
Substance Use & Poisoning

Discovery and preclinical evaluation of dopamine D4 receptor-selective ligand CAB-01-019

April 14, 2023
No Comments
Researchers from High Point University recently reported the discovery and preclinical evaluation of a novel class of highly selective dopamine D4 receptor-selective ligands as potential therapeutic candidates for substance use disorders.
Read More
Substance Use & Poisoning

New opioid receptor modulator has the noncompetitive advantage

March 29, 2023
By Anette Breindl
No Comments
Researchers at Indiana University Bloomington have developed allosteric modulators of the opioid receptor that were superior to the opioid antidote naloxone at blocking the effects of fentanyl in vitro. They presented their work in a session on “Progress towards more efficacious medicine: Antibiotics and antidotes” at the 2023 spring meeting of the American Chemical Society (ACS).
Read More
Illustration of pill being analyzed
Substance Use & Poisoning

Toxicity data reported for VK-4-116 following once-daily oral dosing in rats and dogs

March 27, 2023
No Comments
Researchers from the National Institutes of Health recently presented preclinical data for the dopamine D3 receptor antagonist VK-4-116, which has potential for the treatment of opioid use disorder (OUD).
Read More
Acetaminophen pills
Substance Use & Poisoning

JNJ-26366821 repairs acetaminophen-induced liver injury in mice

March 23, 2023
No Comments
Acetaminophen (APAP) is a very common nonprescription analgesic, harmless at low doses, that can cause acute liver injury and even death from acute liver failure when overdosed. The temporal course of acetaminophen overdose-induced liver injury (AILI) can be depicted in two stages – injury and recovery.
Read More

Resilient develops wearable device to reverse opioid overdoses

March 16, 2023
By Annette Boyle
No Comments
Free, no-prescription-required access to naloxone injectors and nasal sprays has reduced deaths from opioid overdoses by 11% in some communities, but they only work if someone with the reversal agent is available when a person overdoses. Many times, unfortunately, opioid users are alone when an overdose occurs. Resilient Lifescience Inc. hopes to save those lives, too. The company is developing a wearable patch that monitors vital signs and automatically administers naloxone when needed.
Read More
Concept image for radiation syndrome
Substance Use & Poisoning

RNCP selects Redhill's opaganib for evaluation for acute radiation syndrome

March 1, 2023
No Comments
Redhill Biopharma Ltd.'s opaganib hydrochloride (ABC-294640) has been selected by the Radiation and Nuclear Countermeasures Program (RNCP), of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the nuclear medical countermeasures product development pipeline as a potential treatment for acute radiation syndrome (ARS).
Read More
Previous 1 2 3 4 5 6 7 8 9 … 112 113 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 1, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 1, 2023.
  • Cerebellum, brain stem, spinal cord

    Reprocell reports mixed results for phase II Stemchymal trial in spinocerebellar ataxia

    BioWorld
    Regenerative medicine product Stemchymal, an allogeneic adipose-derived mesenchymal stem cell treatment, missed the primary efficacy endpoints in two phase II...
  • Medical cannabis in blister pack of capsules

    Zelira’s stock triples as cannabinoid outperforms Lyrica in pain

    BioWorld
    Medicinal cannabis company Zelira Therapeutics Ltd.’s stock shot up 224% on May 31 on the heels of news that its cannabinoid product, ZLT-L-007, outperformed...
  • EU flag, pills, syringe

    Otsuka’s schizophrenia drug filing U-turn amongst latest CHMP announcements

    BioWorld
    Otsuka Pharmaceutical Co. Ltd. has gone back on efforts to get its medicine, Asimtufii (aripiprazole), a long-acting maintenance treatment for schizophrenia,...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing